Modular Medical Announces Proposed Public Offering
Modular Medical (NASDAQ:MODD) announced on December 9, 2025 that it has commenced an underwritten public offering of shares of its common stock and warrants to purchase common stock.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Modular Medical (NASDAQ:MODD) announced on December 9, 2025 that it has commenced an underwritten public offering of shares of its common stock and warrants to purchase common stock. The common shares and warrants will be issued separately but sold together in the offering. Modular Medical expects to grant the underwriter a 30-day option to purchase up to an additional 15% of the aggregate shares and/or warrants. The offering is being made from an effective Form S-3 shelf registration (File No. 333-287313) declared effective by the SEC on May 22, 2025. Newbridge Securities Corporation is the sole bookrunner. The offering is subject to market conditions and may not be completed as proposed.
Positive
- Offering includes warrants alongside common stock
- Underwriter option provides potential upsizing by 15%
Negative
- Issuance of new shares may dilute existing shareholders
- Completion of the offering is uncertain and market-dependent
Details
News Market Reaction – MODD
On Dec 10, the first trading day after this news, MODD closed 30.47% below the previous close.
Data tracked by StockTitan Argus for the Dec 10 session.
Key Figures
- 30-day option
- 30 days
- Underwriter option to purchase up to an additional 15% of the offering
- Overallotment size
- 15%
- Potential extra shares and/or warrants underwriter may purchase
- Gross proceeds
- $4.4 million
- Warrant exercise proceeds from Sep 29, 2025 offering-related event
- Reduced exercise price
- $0.68 per share
- Price for exercised warrants in Sep 29, 2025 event
- New warrant exercise price
- $0.84 per share
- Exercise price for new unregistered warrants (5-year term)
- New warrants issued
- 3,252,366 warrants
- Unregistered warrants from Sep 29, 2025 financing event
- Ownership stake
- 3.81%
- Alyeska group beneficial ownership of MODD common stock
- Shares outstanding base
- 54,247,388 shares
- Share count used to calculate 3.81% ownership in Schedule 13G/A
Historical Context
-
IRB approval for in-house study using Pivot tubeless patch pump.
-
Submission of Pivot tubeless insulin patch pump for FDA 510(k) clearance.
-
Successful validation of Pivot controller manufacturing line for high-volume use.
-
Stage 1 ISO 13485 audit completed with no major nonconformances.
-
Appointment of Head of International Operations to drive Pivot rollout.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
underwritten public offering financial
warrants financial
form s-3 regulatory
prospectus supplement regulatory
AI-generated analysis. How Rhea-AI works. Not financial advice.
SAN DIEGO, CA / ACCESS Newswire / December 9, 2025 / Modular Medical, Inc. (NASDAQ:MODD) ("Modular Medical"), an insulin delivery technology company with the first FDA-cleared patch pump designed specifically to target all adult "almost-pumpers" with its user-friendly and affordable design, today announced that it has commenced an underwritten public offering (the "offering") of shares of its common stock and warrants to purchase shares of its common stock. The shares of the common stock and the accompanying warrants are immediately separable and will be issued separately but can only be purchased together in this offering.
Modular Medical expects to grant the underwriter a 30-day option to purchase up to an additional
Newbridge Securities Corporation is acting as the sole bookrunner for the proposed offering.
The offering is being made pursuant to an effective "shelf" registration statement on Form S-3 (File No. 333-287313) previously filed with the Securities and Exchange Commission (the "SEC") on May 15, 2025 and declared effective by the SEC on May 22, 2025. The securities may be offered only by means of a prospectus. A preliminary prospectus supplement and the accompanying prospectus relating to and describing the terms of the offering will be filed with the SEC. Electronic copies of the preliminary prospectus supplement and accompanying prospectus and, when available, copies of the final prospectus supplement and the accompanying prospectus relating to the offering may be obtained by visiting the SEC's website at www.sec.gov or by contacting Newbridge Securities Corporation, Attn: Equity Syndicate Department, 1200 North Federal Highway, Suite 400, Boca Raton, Florida 33432, by email at syndicate@newbridgesecurities.com or by telephone at (877) 447-9625.
This press release does not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation, or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or jurisdiction.
About Modular Medical
Modular Medical, Inc. (NASDAQ:MODD) is a medical device company that intends to launch the next generation of insulin delivery technology. Using its patented technologies, the Company seeks to eliminate the tradeoff between complexity and efficacy, thereby making top quality insulin delivery both affordable and simple to learn. Its mission is to improve access to the highest standard of glycemic control for people with diabetes, taking it beyond "superusers" and providing "diabetes care for the rest of us."
Modular Medical was founded by Paul DiPerna, a seasoned medical device professional and microfluidics engineer. Prior to founding Modular Medical, Mr. DiPerna was the founder (in 2005) of Tandem Diabetes and invented and designed its t:slim insulin pump. More information is available at https://modular-medical.com.
All trademarks mentioned herein are the property of their respective owners.
Forward-Looking Statements
This press release contains forward-looking statements that are made pursuant to the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified through the use of words such as "may," "might," "will," "intend," "should," "could," "can," "would," "continue," "expect," "believe," "anticipate," "estimate," "predict," "outlook," "potential," "plan," "seek," and similar expressions and variations or the negatives of these terms or other comparable terminology. Such forward-looking statements are subject to risks, trends, and uncertainties that could cause actual results to be materially different from the forward-looking statements contained in this press release, including whether or when the offering may be completed, as well as other risk factors and business considerations described in Modular Medical's SEC filings, including its annual report on Form 10-K. Any forward-looking statements in this press release should be evaluated in light of these important risk factors. In addition, any forward-looking statements included in this press release represent Modular Medical's views only as of the date of its publication and should not be relied upon as representing its views as of any subsequent date. Modular Medical assumes no obligation to update these forward-looking statements, except as required by law.
Contact Information
Jeb Besser
Chief Executive Officer
Modular Medical, Inc.
+1 (617) 399-1741
IR@modular-medical.com
SOURCE: Modular Medical, Inc.
View the original press release on ACCESS Newswire
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.